Table 3. WWARN Timeline, derived from records review.
DP: dihydroartemisinin-piperaquine; AS-AQ: artesunate –amodiaquine; AL: artemether-lumefantrine; WHO/TDR: The World Health Organization/Special Programme for Research and Training in Tropical Diseases.
| Date | Events |
|---|---|
| 2004 – 2007 | Carol Sibley first presents the idea of WWARN at the 1
st Molecular Approaches to Malaria meeting, 2004.
Side-meetings continued at many malaria/tropical medicine conferences. |
| September 2007 | Seattle Biomedical Research Institute awarded US$1,021,401 by the Bill and Melinda Gates Foundation to begin
planning WWARN. |
| November 2007 | WWARN concept launched at the annual meeting of the American Society of Tropical Medicine and Hygiene. |
| 2008 | Oxford University chosen as a location.
Philippe Guerin chosen as Executive Director. |
| January 2009 | Oxford University awarded US$20,674,222 grant from Bill and Melinda Gates Foundation to implement WWARN. |
| July 2009 | Memorandum of Understanding with WHO. |
| July 2009 | WHO awarded US$7,828,470 grant from the Bill and Melinda Gates Foundation to support for therapeutic efficacy
surveillance studies. |
| 2009 | United States Agency for International Development grant received by Molecular Group in collaboration with
University of Maryland for training of researchers in Southeast Asia. Data Sharing Agreement drafted. |
| 2010 | Development of data sharing software.
Consensus meeting held with WHO. |
| March 2011 | Terms of Submission document finalised. |
| July 2011 | Memorandum of Understanding with GlaxoSmithKline. |
| October 2011 | First study groups launched:
DP Dose Impact AS-AQ/AL Molecular Marker AS-AQ Dose Impact |
| November 2013 | First study group paper published. |
| October 2013 | Grant from ExxonMobil. |
| 2014 | 230 partners working with WWARN.
100,000 individual patient data from 50 endemic countries. Novartis requested use of the Parasite Clearance Estimator model developed by WWARN to register new drugs. Agreement to standardise data collection on core variables, along with flexibility to collect additional variables. |
| 2015 | Change in board structure and membership.
Board approval for development of other disease platforms. |
| 2016 | Provisional agreement with WHO/TDR to develop independent data access committee.
Launch of the Infectious Diseases Data Observatory initiative. |